Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
Sponsor: University of Vermont
Trial Details
| Condition | Opioid Use Disorder, Posttraumatic Stress Disorder |
| Intervention | Prolonged exposure therapy; Financial incentives; Treatment as usual |
| Phase | NA |
| Status | Recruiting |
| Participants | 135 |
| Est. Completion | 31 Aug 2027 |
| Last Updated | 18 May 2026 |
Primary Outcome
Prolonged exposure therapy session attendance; Prolonged exposure therapy completion; Change in posttraumatic stress disorder symptom severity - clinician rated
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * \>18 years old * Maintained on a stable methadone or buprenorphine dose for \>1 month prior to the study * Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5 * Participants receiving psychotropic medications must be maintained on a stable dose for \>1 month prior to enrollment. Exclusion Criteria: * Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview * Cognitive impairment as evidenced by scores \<22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975) * Enrolled in another ongoing evidence-based treatment for PTSD. * Pregnancy as verified by pregnancy test * No access to cellular service
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service